← Eichor
Condition: Metastatic Castration Resistant Prostate Cancer Mcrpc Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Castration Resistant Prostate Cancer Mcrpc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC
Phase 1/Phase 2 · 18 location(s) · Pathos AI, Inc. · NCT06785636Study of AZD0754 in Participants With Metastatic Prostate Cancer
Phase 1/Phase 2 · 15 location(s) · AstraZeneca · NCT06267729A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer
Phase 1/Phase 2 · 12 location(s) · Memorial Sloan Kettering Cancer Center · NCT06457919Prospective Evaluation of Imaging Response Biomarkers During [177Lu]Lu-PSMA in Metastatic Castration-resistant Prostate
Phase N/A · 1 location(s) · University Hospital, Grenoble · NCT06828263ACTinium in Castrate-RESistant Prostate Cancer After LUTEtium
Phase 1/Phase 2 · 1 location(s) · University College, London · NCT07414940ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials
Phase N/A · 3 location(s) · Duke University · NCT06141993A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Re
Phase 1/Phase 2 · 82 location(s) · Merck Sharp & Dohme LLC · NCT06863272A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (
Phase 1 · 19 location(s) · Daiichi Sankyo · NCT07244341Randomized Phase II Trial of Targeted Radiation With no Castration for Mcrpc
Phase 2 · 4 location(s) · VA Office of Research and Development · NCT06084338A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resist
Phase 3 · 329 location(s) · Merck Sharp & Dohme LLC · NCT06136650Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617
Phase 2 · 1 location(s) · Ebrahim S Delpassand · NCT06972628Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 8 location(s) · Acerand Therapeutics (Hong Kong) Limited · NCT06801236A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
Phase 1 · 10 location(s) · Flare Therapeutics Inc. · NCT07719361Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Phase 1 · 8 location(s) · Olema Pharmaceuticals, Inc. · NCT06784193Kidney Function and Risk Factors in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) Undergoing 177
Phase N/A · 1 location(s) · Hannah Schaefer · NCT06720532Radiotherapy Combined With Fluzopanib and Abiraterone Acetate Tablets (II) Treatment for mCRPC
Phase 2 · 1 location(s) · Jianbin Bi · NCT06971211A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate C
Phase 1/Phase 2 · 19 location(s) · GlaxoSmithKline · NCT06990880Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
Phase 2 · 31 location(s) · Dendreon · NCT06134232A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients
Phase 1/Phase 2 · 22 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT06609005Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adu
Phase 2/Phase 3 · 81 location(s) · Novartis Pharmaceuticals · NCT06780670A Multicenter, Open-label, Non-randomized Phase I/IIa Clinical Trial to Evaluate INR102 Injection in Patients With Prost
Phase 1/Phase 2 · 2 location(s) · Yunhe Pharmaceutical (Tianjin) Co., Ltd · NCT06970119Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer
Phase 1 · 1 location(s) · Beijing Biotech · NCT07641049RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
Phase 1/Phase 2 · 1 location(s) · Tianjin Medical University Second Hospital · NCT06663007Intrinsic Validity of Molecular Marker(s) Detection on Tissular Tumoral DNA to Predict the Efficacy of 177Lutetium-PSMA-
NA · 5 location(s) · Centre Jean Perrin · NCT06600802A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants Wit
Phase 3 · 281 location(s) · Celgene · NCT067644853D1015 Injection for Patients With mCRPC
Phase 1 · 1 location(s) · Chunjing Yu · NCT07537010Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC
Phase 2 · 1 location(s) · Erasmus Medical Center · NCT05762536SPECT/CT Imaging for Dosimetry in 177Lu-PSMA-617 (Pluvicto) Therapy
Phase N/A · 1 location(s) · University of Michigan Rogel Cancer Center · NCT07096999A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor
Phase 1 · 3 location(s) · Novartis Pharmaceuticals · NCT07570979An Exploratory Clinical Study Evaluating the Safety and Efficacy of Allogeneic CAR-NK Cell Therapy for Metastatic Castra
EARLY_Phase 1 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07298239
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.